A UK sector view on why a rising health burden the state cannot fund alone has become a question of private capital, and of how that capital is governed.
Healthcare infrastructure investment is rising up the agenda for one plain reason. The metabolic disease burden, type 2 diabetes, obesity, and the heart and kidney conditions that follow are growing faster than any government can comfortably fund. The UK already shows the strain. The NHS spends around £10.7 billion a year on diabetes alone, roughly a tenth of its budget, according to NHS England (2025). Obesity adds a further £12 billion in NHS costs each year. Across the wider economy that figure nears £126 billion, both estimates from Nesta and Frontier Economics (2025).
A bill that size growing every year is the real story for an investor here. No government can carry it alone. The UK has stopped pretending otherwise, and now needs private capital to build and run parts of the system it can no longer fund from tax alone. Univere Investment Solutions treats that shift as a starting point, not a conclusion.
A health burden the state cannot fund alone becomes, by default, a question of private capital, and of who is trusted to govern it.
The cost is not only large; it is locked onto an upward path. Diabetes spending in the UK is projected to reach nearly £18 billion by 2035 if prevalence keeps climbing, according to Diabetes UK (2024). The pattern within that number matters more than the total. Most of the money goes on complications that are largely preventable, so the system is paying to manage failure rather than to prevent it. Lord Darzi’s independent review of the NHS (2024) found a service in deep financial and operational trouble. Rising demand, tight budgets, and an ever widening gap.
More than five million people in the UK now live with diabetes, on Diabetes UK figures, and millions more carry the excess weight that often precedes it, so the bill compounds rather than plateaus.
Why this demand does not fade
What makes this attractive to patient capital is not the size of the bill but its reliability. Chronic illness does not wait for good times. A person managing diabetes needs the same care next year whether the FTSE rises or falls, and clinics, pharmacy networks, and monitoring systems inherit that steadiness. That is the quality patient investors prize most.
Why is the UK opening healthcare to private capital?
Because the state cannot fund the system alone. The Government’s 10 Year Health Plan for England (July 2025) set the direction, and the Autumn Budget 2025 confirmed it, approving a new public-private partnership model for the NHS’s neighbourhood health centres, with private capital used on a case-by-case basis. Tight public finances made that a planned route, not a fallback.
The shift now has money behind it. At the Autumn Budget 2025 the Treasury agreed that private capital can help fund the NHS Neighbourhood Rebuild programme, with most of the first 120 centres built through a new partnership model and the remainder from public funds, on NHS England guidance (2025). The Independent Healthcare Providers Network (November 2025) has pressed for more, calling private investment essential to the plan and proposing a dedicated council to channel capital into healthcare infrastructure.
This is not a blanket opening of the NHS to private money. The new model is restricted, for now, to these neighbourhood centres, and it has critics who remember the cost of older private finance deals. None of this removes the risk to capital. What it does mean is that the direction is set by policy rather than by speculation, which is uncommon in private markets.
Policy opens the door; governance decides the outcome
An open door is not a safe entry. Government backing widens the opportunity, but it does not make any single deal sound on its own. The difference sits in the design. How the capital is arranged, who holds which rights, and what protects investors when an operator stumbles, that is where outcomes are decided.
Univere works to a deliberate discipline. Architecture comes before opportunity. Returns are designed into how an instrument is built, through the rights and protections around it. Access is kept narrow, because suitability protects the investor as much as the issuer. And no single holding is judged on its own, because it earns a place only within a wider private capital allocation. This is the approach behind our healthcare strategy, Health45.
Where this leaves a long-term allocator
For an investor, the case rests on three features that rarely meet in one sector. Demand being large and immune to the cycle. The need for outside capital is now written into UK health policy, rather than merely tolerated at the edges of it. And the assets behave like infrastructure, costly to build and steady to run. That mix is unusual. It rewards patience over speed, and steady discipline over enthusiasm. What the state has opened is both the gap itself and, increasingly, a standing invitation to help fill it.
Demand builds the sector; governance decides who keeps the proceeds.
Univere shares sector commentary of this kind with professional readers who tend to think in allocations rather than in single products. The door it describes stays narrow by design. Qualified professional contacts can find our wider perspective on access and capital design at univereinvestments.com/insights.
Professional access only. Not for public or retail audiences. Univere Investment Solutions Limited is not authorised or regulated by the Financial Conduct Authority. This content does not constitute a financial promotion, financial advice, or an invitation or inducement to engage in investment activity. Past performance is not indicative of future results. Capital is at risk.
